NCT05607199 2026-04-17
BHARAT-1
Aurigene Discovery Technologies Limited
Phase 1 Terminated
Clinical Trials
7 trialsNCT06021600 2026-04-09
A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT05263271 2026-04-06
Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1 Terminated
NCT01366612 2026-04-03
FLUBUTBI
Hackensack Meridian Health
Phase 3 Terminated
NCT03150004 2026-03-30
Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
Medical College of Wisconsin
Phase 2 Terminated
NCT05933070 2026-03-30
LAUREL
Inmune Bio, Inc.
Phase 1 Terminated
NCT06563804 2026-03-30
A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML
Servier
Phase 1/2 Terminated